PEGylated drugs in rheumatology—why develop them and do they work?

Por McDonnell, Thomas, Ioannou, Yiannis, Rahman, Anisur
Publicado em 2014

In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB

Por Vaddady, Pavan K, Lee, Richard E, Meibohm, Bernd
Publicado em 2010

When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development

Por Oraiopoulos, Nektarios, Dunlop, William C. N.
Publicado no Adv Ther (2017)

Relationship between Dose, Drug Levels, and D2 Receptor Occupancy for the Atypical Antipsychotics Risperidone and Paliperidone

Por Muly, E. C., Votaw, J. R., Ritchie, J., Howell, L. L.
Publicado em 2012

Analysis of pramipexole dose–response relationships in Parkinson’s disease

Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)

How Well Are Specialty Injectable Drugs Managed?

Por Marlo, Karen
Publicado em 2004

Deciphering the role of ectosomes in cancer development and progression: focus on the proteome

Por Surman, Magdalena, Stępień, Ewa, Hoja-Łukowicz, Dorota, Przybyło, Małgorzata
Publicado no Clin Exp Metastasis (2017)

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

Por Norata, Giuseppe Danilo, Ballantyne, Christie M., Catapano, Alberico Luigi
Publicado em 2013

Ascidian Toxins with Potential for Drug Development

Por Watters, Dianne J.
Publicado no Mar Drugs (2018)

Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial

Por Kosilov, Kirill Vladimirovich, Loparev, Sergey, Kuzina, Irina, Shakirova, Olga, Zhuravskaya, Nataliya, Lobodenko, Alexandra
Publicado no Ther Adv Urol (2016)

Clozapine-Related EEG Changes and Seizures: Dose and Plasma-Level Relationships

Por Varma, Seema, Bishara, Delia, Besag, Frank M. C., Taylor, David
Publicado em 2011

The Possibilities of Single-Pill Combinations of Antihypertensive Drugs in Cerebroprotection: Focus on the Combination of Amlodipine with Ramipril

Por A. I. Kochetkov, S. V. Batyukina, O. D. Ostroumova, M. Yu. Nazranova, V. N. Butorov
Publicado em 2020-07-01

Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring

Por Kim, Tiffany, Jancel, Timothy, Kumar, Parag, Freeman, Alexandra F.
Publicado no J Clin Pharm Ther (2015)

Xanthine scaffold: scope and potential in drug development

Por Singh, Nivedita, Shreshtha, Ashwinee Kumar, Thakur, M.S., Patra, Sanjukta
Publicado no Heliyon (2018)

Nanoparticle Delivery of Anti-Tuberculosis Chemotherapy as a Potential Mediator Against Drug-Resistant Tuberculosis

Por Smith, Jonathan Paul
Publicado em 2011

Chutes and Ladders in Hepatitis C Nucleoside Drug Development()

Por Coats, Steven J., Garnier-Amblard, Ethel C., Amblard, Franck, Ehteshami, Maryam, Amiralaei, Sheida, Zhang, Hongwang, Zhou, Longhu, Boucle, Sebastien R. L., Lu, Xiao, Bondada, Lavanya, Shelton, Jadd R., Li, Hao, Liu, Peng, Li, Chengwei, Cho, Jong Hyun, Chavre, Satish N., Zhou, Shaoman, Mathew, Judy, Schinazi, Raymond F.
Publicado em 2013

Potential new targets for drug development in severe asthma

Por Zhu, Linda, Ciaccio, Christina E., Casale, Thomas B.
Publicado no World Allergy Organ J (2018)

Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients

Por Okparavero, Aghogho A, Tighiouart, Hocine, Krishnasami, Zipporah, Wyatt, Christina M, Graham, Hiba, Hellinger, James, Inker, Lesley A
Publicado em 2013

Drug development in oncology: classical cytotoxics and molecularly targeted agents

Por Kummar, Shivaani, Gutierrez, Martin, Doroshow, James H, Murgo, Anthony J
Publicado em 2006

Development of a Patient-Centered Bilingual Prescription Drug Label

Por Mohan, Arun, Riley, M. Brian, Boyington, Dane, Johnston, Phillip, Trochez, Karen, Jennings, Callie, Mashburn, Jennie, Kripalani, Sunil
Publicado em 2013